AMRX News and Press, Amneal Pharmaceuticals Inc. Class A From 12/20/21

Whether you’re looking for a Santa Claus Rally or trying to find some tax-loss harvesting opportunities, omicron fears have slapped the market in the face to start the short holiday week. Over the weekend, concerns began to grow thanks to commentary from the scientific community. The...

TherapeuticsMD (NASDAQ:TXMD) announces the settlement of the previously disclosed U.S. patent litigation for Bijuva with Amneal Pharmaceuticals (NYSE:AMRX). TXMD shares up 2% premarket at $0.45. As part of the settlement, TXMD granted to Amneal a license to commercialize latter's ge...

Amneal Pharmaceuticals (NYSE:AMRX) has received Abbreviated New Drug Application (ANDA) approval from the FDA for difluprednate ophthalmic emulsion 0.05%, which is the generic version of Durezol and is used in the treatment of inflammation and pain associated with ocular surgery. According to...

- Represents the latest generic ophthalmic product approval for Amneal Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced that it has received Abbreviated New Drug Application (ANDA) approval from the U.S. Food a...

Image source: The Motley Fool. Amneal Pharmaceuticals, inc (NYSE: AMRX) Q3 2021 Earnings Call Nov 3, 2021 , 8:30 a.m. ET Operator Continue reading For further details see: Amneal Pharmaceuticals, inc (AMRX) Q3 2021 Earnings Call Transcrip...

Amneal Pharmaceuticals, Inc. (AMRX) Q3 2021 Earnings Conference Call Nov 03, 2021 08:30 AM ET Company Participants Tony DiMeo - Head, Investor Relations Chirag Patel - Co-Chief Executive Officer Chintu Patel - Co-Chief Executive Officer Tasos Konidaris - Chief Financial Officer Conference Cal...

The following slide deck was published by Amneal Pharmaceuticals, Inc. in conjunction with their 2021 Q3 earnings call. For further details see: Amneal Pharmaceuticals, Inc. 2021 Q3 - Results - Earnings Call Presentation

Amneal Pharmaceuticals (NYSE:AMRX): Q3 Non-GAAP EPS of $0.21 beats by $0.01; GAAP EPS of -$0.03 misses by $0.11. Revenue of $529M (+1.9% Y/Y) misses by $15.08M. Press Release Updating 2021 Full Year Financial Outlook, Including Raising Adjusted EBITDA and Adjusted EPS Guidance. For further ...

‒ Q3 2021 Net Revenue of $529 million; GAAP Net Loss of $(4) million; Diluted Loss per Share of $(0.03) ‒ ‒ Adjusted EBITDA (1) of $135 million; Adjusted Diluted EPS (1) of $0.21 ‒ ‒ Updating 2021 Full Year Financial Outlo...

Amneal Pharmaceuticals (NYSE:AMRX) is scheduled to announce Q3 earnings results on Wednesday, November 3rd, before market open. The consensus EPS Estimate is $0.20 (+25.0% Y/Y) and the consensus Revenue Estimate is $544.08M (+4.8% Y/Y). Over the last 2 years, AMRX has beaten EPS estimates 88%...